BR112023003866A2 - Medicamento de combinação para o controle e gerenciamento de diabetes melito tipo 2 - Google Patents

Medicamento de combinação para o controle e gerenciamento de diabetes melito tipo 2

Info

Publication number
BR112023003866A2
BR112023003866A2 BR112023003866A BR112023003866A BR112023003866A2 BR 112023003866 A2 BR112023003866 A2 BR 112023003866A2 BR 112023003866 A BR112023003866 A BR 112023003866A BR 112023003866 A BR112023003866 A BR 112023003866A BR 112023003866 A2 BR112023003866 A2 BR 112023003866A2
Authority
BR
Brazil
Prior art keywords
type
control
management
diabetes
melitos
Prior art date
Application number
BR112023003866A
Other languages
English (en)
Inventor
Yazmín Ollervides Rubio Paola
Serafín Espinoza León Sixto
Cuahutencos Escobar Ernesto
Alejandro González Canudas Jorge
Original Assignee
Laboratorios Silanes S A De C V
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios Silanes S A De C V filed Critical Laboratorios Silanes S A De C V
Publication of BR112023003866A2 publication Critical patent/BR112023003866A2/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/64—Sulfonylureas, e.g. glibenclamide, tolbutamide, chlorpropamide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

MEDICAMENTO DE COMBINAÇÃO PARA O CONTROLE E GERENCIAMENTO DE DIABETES MELITO TIPO 2. A presente invenção refere-se a um medicamento inovador de liberação imediata estável para o tratamento, controle e melhor gerenciamento do diabetes melito tipo 2 contendo uma sulfonilureia como glimepirida, um inibidor da dipeptidil peptidase-4 (DPP4) como a vildagliptina, e uma biguanida como a metformina. Ao mesmo tempo, a presente invenção permite resolver um conjunto de importantes desafios tecnológicos na fabricação de tal medicamento devido às propriedades físico-químicas e à diferença na dosagem da combinação sinérgica dos fármacos.
BR112023003866A 2020-09-02 2020-09-02 Medicamento de combinação para o controle e gerenciamento de diabetes melito tipo 2 BR112023003866A2 (pt)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/MX2020/050030 WO2022050832A1 (es) 2020-09-02 2020-09-02 Medicamento de combinación para el control y manejo de la diabetes mellitus tipo 2

Publications (1)

Publication Number Publication Date
BR112023003866A2 true BR112023003866A2 (pt) 2023-04-04

Family

ID=80491336

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023003866A BR112023003866A2 (pt) 2020-09-02 2020-09-02 Medicamento de combinação para o controle e gerenciamento de diabetes melito tipo 2

Country Status (11)

Country Link
US (1) US20230310462A1 (pt)
EP (1) EP4180045A4 (pt)
JP (1) JP2023543393A (pt)
KR (1) KR20230074742A (pt)
BR (1) BR112023003866A2 (pt)
CA (1) CA3191302A1 (pt)
CO (1) CO2023004272A2 (pt)
DO (1) DOP2023000044A (pt)
MX (1) MX2022015333A (pt)
PE (1) PE20231437A1 (pt)
WO (1) WO2022050832A1 (pt)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200637839A (en) 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
MX2013000824A (es) 2010-07-21 2013-10-28 Nucitec Sa De Cv Forma de dosificacion diaria unica para la prevencion y tratamiento del sindrome metabolico.
MX339374B (es) 2011-04-29 2016-05-13 Inst De Investigación En Química Aplic S A De C V Cocristales ionicos con base en metformina.
US20160151382A1 (en) * 2013-10-08 2016-06-02 Kevin Ray Pickering Cooperative Medication Combination Systems
WO2016034710A1 (en) * 2014-09-05 2016-03-10 Sanovel Ilac Sanayi Ve Ticaret A.S. Pharmaceutical combinations of sitagliptin
KR20180002460A (ko) * 2016-06-29 2018-01-08 주식회사 엘지화학 제2형 당뇨병 및 당뇨성 이상지질혈증 치료용 조성물, 키트 및 병용 요법
BR112021018973A2 (pt) * 2019-03-25 2022-02-01 The George Inst For Global Health Formulação de combinação tripla de baixa dose

Also Published As

Publication number Publication date
JP2023543393A (ja) 2023-10-16
US20230310462A1 (en) 2023-10-05
MX2022015333A (es) 2023-01-11
EP4180045A4 (en) 2024-04-10
CO2023004272A2 (es) 2023-06-20
DOP2023000044A (es) 2023-04-30
KR20230074742A (ko) 2023-05-31
CA3191302A1 (en) 2022-03-10
PE20231437A1 (es) 2023-09-14
EP4180045A1 (en) 2023-05-17
WO2022050832A1 (es) 2022-03-10

Similar Documents

Publication Publication Date Title
DOP2023000168A (es) Compuestos antivirales que contienen nitrilo
ECSP16096962A (es) Composición para tratar diabetes, que contiene un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
BR112014031375A2 (pt) moduladores da série de reação complementar e usos dos mesmos
CY1114215T1 (el) Φαρμακευτικες συνθεσεις διαλυματος για υπο πιεση εισπνευστηρες μετρουμενης δοσης
BR112014032734A2 (pt) derivados de pirrolidina e seu uso como moduladores da série de reação de complemento
BR112013017316A2 (pt) compostos de indol ou análogos dos mesmos para o tratamento de degeneração macular relacionada à idade (amd)
BR112022022024A2 (pt) Uso de um componente (i) em combinação com um componente (ii), composição farmacêutica, medicamento composto e kit
BRPI0718596B8 (pt) composições farmacêuticas para terapia de combinação com inibidores de sglt-2 e metformina
UY29694A1 (es) Metodos para prevenir y tratar trastornos metabolicos y nuevos derivados de pirazol-o-glucosido
BR112021019256A2 (pt) Moduladores de receptor x4 de proteína g relacionado a mas e produtos e métodos relacionados
BR112013006344A2 (pt) lactamas substituídas por piperdinila como moduladores de gpr119, composição farmacêutica as compreendendo, uso e processso para preparação das mesmas
BR112013026257A2 (pt) derivados de glicosídeo e usos dos mesmos para o tratamento de diabetes
PT2576524T (pt) Resumo
BR112018072755A2 (pt) composto de fórmula geral, processo para a preparação, composto para uso e composição farmacêutica
BR112021018973A2 (pt) Formulação de combinação tripla de baixa dose
BR112023003866A2 (pt) Medicamento de combinação para o controle e gerenciamento de diabetes melito tipo 2
BR112022014706A2 (pt) Moduladores da via de resposta integrada ao estresse
BR112022014561A2 (pt) Molécula de ligação de antígeno anti-cd137 para uso no tratamento de câncer
BR112022003183A2 (pt) Usos do inibidor de dpp-iv e de uma combinação do inibidor de dpp-iv e metformina, composição farmacêutica e combinação para retardar perda do controle glicêmico
BRPI0923373B8 (pt) composições farmacêuticas compreendendo uma combinação de insulina com derivados de triazina, e uso da dita combinação
BR112012026005A2 (pt) composições e métodos para tratar diabetes do tipo ii e distúrbios relacionados
BR112022019198A2 (pt) Composição farmacêutica para a prevenção ou tratamento de infecções por vírus de ácido ribonucleico epidêmico, e, uso de uma quantidade terapeuticamente eficaz de pironaridina ou um sal farmaceuticamente aceitável da mesma e artemisinina ou um derivado da mesma
BRPI0607558A2 (pt) derivados do ácido aminobutanóico, inibidor da carnitina palmitoil transferase(cpt)
BR112021018994A2 (pt) Formulação de combinação tripla de baixa dose
BR112023021761A2 (pt) Regime de dosagem de anti-ifnar1 para injeção subcutânea